奥马珠单抗治疗大疱性类天疱疮。
Omalizumab therapy for bullous pemphigoid.
作者信息
Yu Kenneth K, Crew Ashley B, Messingham Kelly A N, Fairley Janet A, Woodley David T
机构信息
Keck School of Medicine, University of Southern California, Los Angeles, California.
Carver College of Medicine, University of Iowa, Iowa City, Iowa.
出版信息
J Am Acad Dermatol. 2014 Sep;71(3):468-74. doi: 10.1016/j.jaad.2014.04.053. Epub 2014 Jun 20.
BACKGROUND
Bullous pemphigoid (BP) responds to a variety of immunosuppressive agents and usually controls, but does not cure, the disease. Omalizumab, Food and Drug Administration-approved for asthma, selectively suppresses the activity of IgE, an important immunoglobulin in the pathogenesis of BP.
OBJECTIVE
We wished to determine if systemic omalizumab would have a therapeutic effect in patients with BP.
METHODS
We treated 6 patients with BP using omalizumab and followed up their disease for up to 42 months.
RESULTS
Although variable, 5 of the 6 patients with BP received therapeutic benefit from systemic omalizumab (the sixth terminated treatment because of intercurrent illness) with less use of other immunosuppressants, inhibition of new bullae, less pruritus, and dramatic decreases in eosinophil counts. None of the patients had untoward side effects from omalizumab.
LIMITATIONS
This was an open, uncontrolled study.
CONCLUSIONS
Omalizumab neutralizes the activity of IgE in patients with BP and improves the control of their disease activity.
背景
大疱性类天疱疮（BP）对多种免疫抑制剂有反应，通常能控制病情，但无法治愈。奥马珠单抗已获美国食品药品监督管理局批准用于治疗哮喘，它能选择性抑制IgE的活性，而IgE是BP发病机制中的一种重要免疫球蛋白。
目的
我们希望确定全身性使用奥马珠单抗对BP患者是否有治疗效果。
方法
我们使用奥马珠单抗治疗了6例BP患者，并对其病情进行了长达42个月的随访。
结果
尽管情况各异，但6例BP患者中有5例从全身性使用奥马珠单抗中获得了治疗益处（第6例因并发疾病而终止治疗），使用的其他免疫抑制剂减少，新水疱形成受到抑制，瘙痒减轻，嗜酸性粒细胞计数显著下降。所有患者均未出现奥马珠单抗的不良副作用。
局限性
这是一项开放性、非对照研究。
结论
奥马珠单抗可中和BP患者体内IgE的活性，并改善对其疾病活动的控制。
Zotero 插件